Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate

2015 ◽  
Vol 76 (3) ◽  
pp. 439-445 ◽  
Author(s):  
Roberto Petrioli ◽  
Edoardo Francini ◽  
Letizia Laera ◽  
Anna Ida Fiaschi ◽  
Roberto Ponchietti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide

2020 ◽  
Vol 72 (6) ◽  
Author(s):  
Consuelo Buttigliero ◽  
Marcello Tucci ◽  
Cristina Sonetto ◽  
Francesca Vignani ◽  
Rosario F. Di Stefano ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Prognostic Role ◽  
Castration Resistant

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Fred Saad ◽  
Neal D Shore ◽  
Hendrik Van Poppel ◽  
Dana Rathkopf ◽  
Matthew R. Smith ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Interim Analysis ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Prior Chemotherapy ◽  
Castration Resistant

scholarly journals Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients

2020 ◽  
Vol 3 (1) ◽  
pp. 119-127 ◽  
Author(s):  
Eleni Efstathiou ◽  
Mark Titus ◽  
Sijin Wen ◽  
Patricia Troncoso ◽  
Anh Hoang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

2015 ◽  
Vol 21 (14) ◽  
pp. 3170-3177 ◽  
Author(s):  
Xu S. Xu ◽  
Charles J. Ryan ◽  
Kim Stuyckens ◽  
Matthew R. Smith ◽  
Fred Saad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

2016 ◽  
Vol 15 (3) ◽  
pp. e772-e772a
Author(s):  
C. Van Praet ◽  
S. Rottey ◽  
F. Van Hende ◽  
G. Pelgrims ◽  
W. Demey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Anne-Emmanuella Yeo ◽  
Aurore Hendrix ◽  
Caterina Confente ◽  
Nicolas Christian ◽  
Baudouin Mansvelt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Liver Metastases ◽  
Poor Prognosis ◽  
Prostate Cancer Patient ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Visceral Metastases ◽  
Isolated Liver

Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.

Sign in / Sign up

Export Citation Format

Share Document